Clinical Data Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial PharmaTimesResponders achieved weight loss and improvements in physical functionMetabolic & GLP-1Read full story pharminent May 13, 2026 (Last updated: May 21, 2026) PharmaTimes Responders achieved weight loss and improvements in physical function Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: UAE approves AstraZeneca’s Baxfendy for hypertensionNext: Clock starts ticking on UK’s single patient record plan Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
